Cuorips
Japan - TokyoBiotechnology
Focus: Cuorips is a Japanese biotechnology company specializing in iPS cell-derived cardiomyocyte sheets for regenerative cell therapy. The company operates as a publicly-traded entity focused on metabolic diseases and cell therapy modalities.
Profile data last refreshed 2d ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Cuorips
AI assessmentNot HiringNo open roles listed right now. Follow Cuorips to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Human
Myocardial IschemiaClinical Trials (1)
NCT04696328Clinical Trial of Human (Allogeneic) iPS Cell-derived Cardiomyocytes Sheet for Ischemic Cardiomyopathy
Phase 1Help build intelligence for Cuorips
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.